JZL195

JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively[1].

Product Specifications

CAS Number

[1210004-12-8]

UNSPSC

12352005

Hazard Statement

H400

Target

Autophagy; FAAH; MAGL

Type

Reference compound

Related Pathways

Autophagy; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/JZL195.html

Concentration

10mM

Purity

99.75

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(OC1=CC=C([N+]([O-])=O)C=C1)N(CC2)CCN2CC3=CC(OC4=CC=CC=C4)=CC=C3

Molecular Formula

C24H23N3O5

Molecular Weight

433.46

Precautions

H400

References & Citations

[1]Long JZ, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A. 2009 Dec 1;106 (48) :20270-5.|[2]Anderson WB, et al. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model. Neuropharmacology. 2014 Jun;81:224-30.